NCT06335160View on ClinicalTrials.gov

Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

May 31, 2025

Conditions

Ulcerative Colitis

Interventions

DRUG

Mebendazole

mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months

All Listed Sponsors

lead

Tanta University

OTHER

NCT06335160 - Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine | Biotech Hunter | Biotech Hunter